Table 1.
Relative abundances of minor trastuzumab charge variants. Relative abundances of several low-level modifications (succinimide on HC-D102, lysine on C-terminus, 1 x sialic acid N-glycoform +/- deamidation of LC-N30, and 2 x sialic acid N-glycoform) are shown as a percentage. Adjusted XDC peak areas represent only the main peak portion of the XDC total area under the curve reported by BioPharma Finder software. Relative abundances were calculated as the sum of the adjusted XDC peak areas of the top 3 glycoforms combined with each of the charge-bearing PTMs shown, divided by the sum of the XDC peak areas of the top 3 main peak glycoforms.
| Main Peak | Adjusted XDC Peak Area | Abundance Relative to Main Peak |
|---|---|---|
| G0F/G0F | 1.34E+ 08 | |
| G0F/G1F | 9.32E+ 07 | |
| G1F/G1F | 3.99E+ 07 | |
| Sum |
2.67E+ 08 |
100.00% |
| Succinimide (HC D102) |
Adjusted XDC Peak Area |
Abundance Relative to Main Peak |
| G0F/G0F, 1 × Succinimide | 5.67E+ 06 | |
| G0F/G1F, 1 × Succinimide | 2.90E+ 06 | |
| G1F/G1F, 1 × Succinimide | 5.21E+ 05 | |
| Sum |
9.10E+ 06 |
3.41% |
| Lysine (C-term) |
Adjusted XDC Peak Area |
Abundance Relative to Main Peak |
| G0F/G0F, 1 × Lysine | 2.78E+ 06 | |
| G0F/G1F, 1 × Lysine | 8.89E+ 05 | |
| G1F/G1F, 1 × Lysine | 1.31E+ 05 | |
| Sum |
3.80E+ 06 |
1.42% |
| 1 × S1GXF |
Adjusted XDC Peak Area |
Abundance Relative to Main Peak |
| G0F/S1G0F | 2.23E+ 06 | |
| G0F/S1G1F | 2.83E+ 06 | |
| G1F/S1G1F | 1.52E+ 06 | |
| Sum |
6.59E+ 06 |
2.47% |
| 1 x S1GXF, 1 x Deamidation (LC N30) |
Adjusted XDC Peak Area |
Abundance Relative to Main Peak |
| G0F/S1G0F, 1 × Deamidation | 2.26E+ 05 | |
| G0F/S1G1F, 1 × Deamidation | 7.07E+ 05 | |
| G1F/S1G1F, 1 × Deamidation | 2.62E+ 05 | |
| Sum |
1.19E+ 06 |
0.45% |
| 2 x S1GXF |
Adjusted XDC Peak Area |
Abundance Relative to Main Peak |
| S1G0F/S1G0F | 4.18E+ 05 | |
| S1G0F/S1G1F | 6.35E+ 05 | |
| S1G1F/S1G1F | 2.61E+ 05 | |
| Sum | 1.31E+ 06 | 0.49% |